Manufacturer
Amgen, Inc
9 drugs, 21 product strengths, 12 recalls on record.
Drugs Amgen, Inc makes
OtezlaNo changeBrand · apremilastPharmacies pay from$98.76Medicare price 2027AranespNo changeBrand · darbepoetin alfaPharmacies pay from$751EpogenNo changeBrand · epoetin alfaPharmacies pay from$323Aimovig-0.1%Brand · erenumabNo weekly priceCorlanor-0.1%Brand · ivabradinePharmacies pay from$300Being discontinued2 open recallsNeupogenNo changeBrand · filgrastimPharmacies pay from$3252 open recallsProliaNo changeBrand · denosumabNo weekly price1 open recallXgevaNo changeBrand · denosumabPharmacies pay from$3,403SensiparBrand · cinacalcetNo weekly price3 open recalls
Recalls
Class IIOngoingJul 1, 2026CorlanorPresence of Foreign Substance.Amgen, Inc. · D-0612-2026Class IIOngoingJul 1, 2026SensiparCGMP DeviationsAmgen, Inc. · D-0613-2026Class IIOngoingJul 1, 2026SensiparCGMP DeviationsAmgen, Inc. · D-0614-2026Class IIOngoingJul 1, 2026CorlanorPresence of Foreign Substance.Amgen, Inc. · D-0615-2026Class IIOngoingJul 1, 2026SensiparCGMP DeviationsAmgen, Inc. · D-0616-2026Class IIOngoingMar 26, 2025NeupogenStability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.Amgen, Inc. · D-0285-2025Class IIOngoingMar 26, 2025NeupogenStability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.Amgen, Inc. · D-0286-2025Class IITerminatedMay 18, 2022MVASI (bevacizumab-awwb)Defective container: loose crimp defect, potential loss of container integrity.Amgen, Inc. · D-0855-2022Class IITerminatedSep 27, 2017ProcritPresence of particulate matter: glass flakes identified as lamellae observed during a routine quality inspection.Amgen, Inc. · D-1173-2017Class IITerminatedAug 23, 2017Procrit Epoetin Alfa 40Presence of particulate matter: Visible glass flakes identified as lamellae in some drug product vials.Amgen, Inc. · D-1086-2017Class IITerminatedDec 28, 2016AMGEN KyprolisLack of Assurance of Sterility: Potential cracks in glass vialsAmgen, Inc. · D-0226-2017Class IITerminatedNov 13, 2013Prolia (denosumab) InjectionPresence of Particulate Matter: Visible cellulose fibers were observed in a small number of prefilled syringes during a routine quality examination.Amgen, Inc. · D-66318-001
About Amgen, Inc
No comments yet. Questions, tips, what worked for you - start the conversation.